Current Partnering Activities
- Out-Licensing of EvitarTM (TTX 333) - Prevention of Adhesion Formation following abdominal/pelvic surgery:
- Markets available: Japan, China, S. Korea, ASEAN, Australia, India, MENA, CIS, Russia and LATAM for EvitarTM. The first drug shown in clinical trials to prevent adhesion formation following laparoscopic surgery. For more information please contact us.
- Option to license at IND or Phase 1 (build to buy) of TTX 332-Prevention of Delayed Graft Function following transplant:
- Worldwide markets available
- Temple will conduct preclinical and clinical work in conjunction with partner
- Option to license at IND or Phase 1 (build to buy) of TTX 334 Oncology platform:
- Worldwide markets available
- Researcher and Temple team have identified chemo resistant ovarian cancer as the preferred lead indication
- Data available in other cancers which can also be developed in conjunction with partner
Companies with a focus in the following areas would be interested in Temple's hospital and acute care portfolio:
- Hospital and acute care
- Oncology
- Transplant
- Women’s health
- Surgery
- Fibrosis
Our medical advisors, collaborators and researchers work at the following organizations.
